Warning letter
Lopez Gonzalez Santana Corporation dba Domel and dba Dermixx: warning letter of Jul 16, 2018
FDA warning letter 524175 · San Juan District Office
Key facts
| Reference number | 524175 |
|---|---|
| Company | Lopez Gonzalez Santana Corporation dba Domel and dba Dermixx |
| Subject | CGMP/Dietary Supplement/Adulterated/Misbranded |
| Issue date | Jul 16, 2018 |
| Posted date | Jul 17, 2018 |
| Issuing office | San Juan District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 101.4, 101.5, 101.36, 111, 111.55, 111.65, 111.103, 111.105, 111.503, 111.553, 111.560, 111.570 and 21 more |
| Inspection city | Rio Piedras |
| Inspection ZIP | 00924 |
| Inspection start date | Jan 31, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: